June 19, 2023
3 min watch
Save
VIDEO: Alliance study shows two-drug combination has better results than three in CLL
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
Choi, a hematologist/oncologist at UC San Diego Moores Cancer Center, highlighted the study, which examined the impact of adding venetoclax (Venclexta; Genentech, AbbVie) to the standard combination therapy of ibrutinib (Imbruvica; Pharmacyclics, Janssen) and obinutuzumab (Gazyva, Genentech) in older patients with CLL.
“This was one example where we learned that when we balance all factors, safety and efficacy, it turns out that more isn’t always better,” Choi said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Choi reports receiving research funding for his institution from AbbVie, AstraZeneca, Beigene, Geron, MEI Pharma, Merck, Oncternal Therapeutics, Pharmacyclics, Protagonist Therapeutics and VelosBio, and noncompensated consulting for AbbVie.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.